Bojana Subotic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bojana Subotic has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandar Neskovic
Clinic of Cardiology, University Clinical Center Zemun, 11080 Belgrade, Serbia
5 shared publications - Boris Dzudovic
Medical Faculty of the Military Medical Academy, University of Defence, 17 Crnotravska, 11000 Belgrade, Serbia
5 shared publications - Irena Mitevska
Clinic of Cardiology, Clinical Center Skopje, Skopje, North Macedonia; Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Skopje, North Macedonia, North Macedonia
5 shared publications - Jovan Matijasevic
Clinic for Intensive Care Medicine and Pulmonary Vascular Diseases, Institute for Pulmonary Diseases Vojvodina, 21204 Sremska Kamenica, Serbia
5 shared publications - Marija Benic
Clinic for Intensive Care Medicine and Pulmonary Vascular Diseases, Institute for Pulmonary Diseases Vojvodina, 21204 Sremska Kamenica, Serbia
5 shared publications - Slobodan Obradovic
Medical Faculty of the Military Medical Academy, University of Defence, 17 Crnotravska, 11000 Belgrade, Serbia
5 shared publications
Latest Publications
- Open Access
- 7 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (13) , 2130
Malignancy as a Predictor and Potential Modifier of Laboratory Biomarker Prognostic Value in Acute Pulmonary Embolism
Background/Objectives: Acute pulmonary embolism (PE) is a major cause of cardiovascular mortality, with prognosis influenced by hemodynamic status, comorbidities, and biomarker profiles. Although several laboratory markers have demonstrated prognostic relevance in PE, it remains unclear whether their predictive performance differs in patients with active malignancy. This study aimed to identify laboratory predictors of in-hospital mortality in acute PE and evaluate the modifying effect of malignancy on biomarker-based prognostic stratification. Methods: This retrospective multicenter cohort study included 2803 consecutive patients with confirmed acute PE enrolled in the Regional Pulmonary Embolism Registry (REPER) between January 2015 and April 2026. Univariate and multivariable logistic regression analyses were performed to identify predictors of in-hospital mortality in the overall cohort and subgroups stratified by malignancy status. Interaction analyses were used to formally assess effect modification by malignancy. Results: Active malignancy was present in 14.02% of patients, and overall in-hospital mortality was 11.10%. Multivariable analysis identified malignancy, CRP, glucose, creatinine clearance (CrCl), platelet count, and ESC risk category as independent predictors of in-hospital mortality. In-hospital mortality was significantly higher in patients with malignancy compared with those without (16.54% vs. 10.21%, p < 0.001). In the malignant subgroup, CRP and glucose remained independent predictors, whereas in non-malignant patients, CRP, glucose, CrCl, and ESC risk category were independently associated with outcome. Significant interactions between malignancy status and CrCl, age, glucose, and total leukocyte count suggest that the prognostic contribution of these variables may differ according to cancer status. Conclusions: Active malignancy is an independent predictor of in-hospital mortality in acute PE and appears to be associated with a more severe presentation. Our findings suggest that malignancy may also modify the prognostic performance of certain biomarkers. These observations suggest that conventional risk stratification tools may require cautious, malignancy-aware interpretation and that prospective studies validating malignancy-adapted prognostic frameworks are warranted.
- 7 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (13) , 2130
Open AccessMalignancy as a Predictor and Potential Modifier of Laboratory Biomarker Prognostic Value in Acute Pulmonary Embolism
Background/Objectives: Acute pulmonary embolism (PE) is a major cause of cardiovascular mortality, with prognosis influenced by hemodynamic status, comorbidities, and biomarker profiles. Although several laboratory markers have demonstrated prognostic relevance in PE, it remains unclear whether their predictive performance differs in patients with active malignancy. This study aimed to identify laboratory predictors of in-hospital mortality in acute PE and evaluate the modifying effect of malignancy on biomarker-based prognostic stratification. Methods: This retrospective multicenter cohort study included 2803 consecutive patients with confirmed acute PE enrolled in the Regional Pulmonary Embolism Registry (REPER) between January 2015 and April 2026. Univariate and multivariable logistic regression analyses were performed to identify predictors of in-hospital mortality in the overall cohort and subgroups stratified by malignancy status. Interaction analyses were used to formally assess effect modification by malignancy. Results: Active malignancy was present in 14.02% of patients, and overall in-hospital mortality was 11.10%. Multivariable analysis identified malignancy, CRP, glucose, creatinine clearance (CrCl), platelet count, and ESC risk category as independent predictors of in-hospital mortality. In-hospital mortality was significantly higher in patients with malignancy compared with those without (16.54% vs. 10.21%, p < 0.001). In the malignant subgroup, CRP and glucose remained independent predictors, whereas in non-malignant patients, CRP, glucose, CrCl, and ESC risk category were independently associated with outcome. Significant interactions between malignancy status and CrCl, age, glucose, and total leukocyte count suggest that the prognostic contribution of these variables may differ according to cancer status. Conclusions: Active malignancy is an independent predictor of in-hospital mortality in acute PE and appears to be associated with a more severe presentation. Our findings suggest that malignancy may also modify the prognostic performance of certain biomarkers. These observations suggest that conventional risk stratification tools may require cautious, malignancy-aware interpretation and that prospective studies validating malignancy-adapted prognostic frameworks are warranted.
- Open Access
- 5 June 2026
- Published by MDPI AG in Preprints.org
Malignancy as a Predictor and Potential Modifier of Laboratory Biomarker Prognostic Value in Acute Pulmonary Embolism
Background/Objectives: Acute pulmonary embolism (PE) is a major cause of cardio-vascular mortality, with prognosis influenced by hemodynamic status, comorbidities, and biomarker profiles. Although several laboratory markers have demonstrated prog-nostic relevance in PE, it remains unclear whether their predictive performance differs in patients with active malignancy. This study aimed to identify laboratory predictors of in-hospital mortality in acute PE and to evaluate the modifying effect of malignancy on biomarker-based prognostic stratification. Methods: This retrospective multicenter cohort study included 2803 consecutive patients with computed tomography-confirmed acute PE enrolled in the Regional Pulmonary Embolism Registry (REPER) between January 2015 and April 2026. Univariate and multivariable logistic regression analyses were performed to identify predictors of in-hospital mortality in the overall cohort and in subgroups stratified by malignancy status. Interaction analyses were used to assess effect modification by malignancy. Results: Active malignancy was present in 14.02% of patients, while overall in-hospital mortality was 14.93%. In the overall cohort, multivariable analysis identified malignancy (OR 1.698, 95% CI 1.128–2.555, p = 0.011), C-reactive protein (CRP), glucose, creatinine clearance (CrCl), platelet count, and white blood cell count as independent predictors of in-hospital mortality (BNP was excluded from multivariable models due to missing data). Mortality was significantly higher in patients with ma-lignancy compared with those without (20.9% vs. 13.2%, p < 0.001). In patients with malignancy, CRP and glucose remained independent predictors, whereas in non-malignant patients, CRP, glucose, and CrCl were independently associated with mortality. Significant interaction effects were observed for CrCl, age, glucose, and white blood cell count. Conclusions: Malignancy is an important predictor of in-hospital mortality in acute PE and may partially influence the prognostic performance of certain conventional biomarkers. These findings suggest that while standard risk markers remain broadly reliable, specific parameters might benefit from a cautious, malignancy-aware interpretation.
- 5 June 2026
- Published by MDPI AG in Preprints.org
Open AccessMalignancy as a Predictor and Potential Modifier of Laboratory Biomarker Prognostic Value in Acute Pulmonary Embolism
Background/Objectives: Acute pulmonary embolism (PE) is a major cause of cardio-vascular mortality, with prognosis influenced by hemodynamic status, comorbidities, and biomarker profiles. Although several laboratory markers have demonstrated prog-nostic relevance in PE, it remains unclear whether their predictive performance differs in patients with active malignancy. This study aimed to identify laboratory predictors of in-hospital mortality in acute PE and to evaluate the modifying effect of malignancy on biomarker-based prognostic stratification. Methods: This retrospective multicenter cohort study included 2803 consecutive patients with computed tomography-confirmed acute PE enrolled in the Regional Pulmonary Embolism Registry (REPER) between January 2015 and April 2026. Univariate and multivariable logistic regression analyses were performed to identify predictors of in-hospital mortality in the overall cohort and in subgroups stratified by malignancy status. Interaction analyses were used to assess effect modification by malignancy. Results: Active malignancy was present in 14.02% of patients, while overall in-hospital mortality was 14.93%. In the overall cohort, multivariable analysis identified malignancy (OR 1.698, 95% CI 1.128–2.555, p = 0.011), C-reactive protein (CRP), glucose, creatinine clearance (CrCl), platelet count, and white blood cell count as independent predictors of in-hospital mortality (BNP was excluded from multivariable models due to missing data). Mortality was significantly higher in patients with ma-lignancy compared with those without (20.9% vs. 13.2%, p < 0.001). In patients with malignancy, CRP and glucose remained independent predictors, whereas in non-malignant patients, CRP, glucose, and CrCl were independently associated with mortality. Significant interaction effects were observed for CrCl, age, glucose, and white blood cell count. Conclusions: Malignancy is an important predictor of in-hospital mortality in acute PE and may partially influence the prognostic performance of certain conventional biomarkers. These findings suggest that while standard risk markers remain broadly reliable, specific parameters might benefit from a cautious, malignancy-aware interpretation.
- Open Access
- 28 September 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (19) , 6269
Association of Blood Leukocytes and Hemoglobin with Hospital Mortality in Acute Pulmonary Embolism
This study aimed to assess the prognostic significance of total leukocyte count (TLC) and hemoglobin (Hb) levels upon admission for patients with acute pulmonary embolism (PE), considering the European Society of Cardiology (ESC) model for mortality risk. 1622 patients from a regional PE registry were included. Decision tree statistics were employed to evaluate the prognostic value of TLC and Hb, both independently and in conjunction with the ESC model. The results indicated all-cause and PE-related in-hospital mortality rates of 10.7% and 6.5%, respectively. Subgrouping patients based on TLC cut-off values (≤11.2, 11.2–16.84, >16.84 × 109/L) revealed increasing all-cause mortality risks (7.0%, 11.8%, 30.2%). Incorporating Hb levels (≤126 g/L or above) further stratified the lowest risk group into two strata with all-cause mortality rates of 10.1% and 4.7%. Similar trends were observed for PE-related mortality. Notably, TLC improved risk assessment for intermediate–high-risk patients within the ESC model, while Hb levels enhanced mortality risk stratification for lower-risk PE patients in the ESC model for all-cause mortality. In conclusion, TLC and Hb levels upon admission can refine the ESC model’s mortality risk classification for patients with acute PE, providing valuable insights for improved patient management.
- 28 September 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (19) , 6269
Open AccessAssociation of Blood Leukocytes and Hemoglobin with Hospital Mortality in Acute Pulmonary Embolism
This study aimed to assess the prognostic significance of total leukocyte count (TLC) and hemoglobin (Hb) levels upon admission for patients with acute pulmonary embolism (PE), considering the European Society of Cardiology (ESC) model for mortality risk. 1622 patients from a regional PE registry were included. Decision tree statistics were employed to evaluate the prognostic value of TLC and Hb, both independently and in conjunction with the ESC model. The results indicated all-cause and PE-related in-hospital mortality rates of 10.7% and 6.5%, respectively. Subgrouping patients based on TLC cut-off values (≤11.2, 11.2–16.84, >16.84 × 109/L) revealed increasing all-cause mortality risks (7.0%, 11.8%, 30.2%). Incorporating Hb levels (≤126 g/L or above) further stratified the lowest risk group into two strata with all-cause mortality rates of 10.1% and 4.7%. Similar trends were observed for PE-related mortality. Notably, TLC improved risk assessment for intermediate–high-risk patients within the ESC model, while Hb levels enhanced mortality risk stratification for lower-risk PE patients in the ESC model for all-cause mortality. In conclusion, TLC and Hb levels upon admission can refine the ESC model’s mortality risk classification for patients with acute PE, providing valuable insights for improved patient management.
- Open Access
- 30 August 2023
- Published by MDPI AG in Preprints.org
Association of Blood Leukocytes and Hemoglobin with Hospital Mortality in Acute Pulmonary Embolism
This study aimed to assess the prognostic significance of total leukocyte count (TLC) and hemoglobin (Hb) levels upon admission for patients with acute pulmonary embolism (PE), considering the European Society of Cardiology (ESC) model for mortality risk. 1622 patients from a regional PE registry were included. Decision tree statistics were employed to evaluate TLC and Hb's prognostic value, both independently and in conjunction with the ESC model. Results indicated all-cause and PE-related in-hospital mortality rates of 10.7% and 6.5% respectively. Subgrouping patients based on TLC cutoff values (≤11.2, 11.2-16.84, >16.84 x10^9/L) revealed increasing all-cause mortality risks (7.0%, 11.8%, 30.2%). Incorporating Hb levels (≤126 g/L or above) further stratified the lowest risk group into two strata with all-cause mortality rates of 10.1% and 4.7%. Similar trends were observed for PE-related mortality. Notably, TLC improved risk assessment for intermediate-high risk patients within the ESC model, while Hb levels enhanced mortality risk stratification for lower risk PE patients in the ESC model for all-cause mortality. In conclusion, TLC and Hb levels upon admission can refine the ESC model's mortality risk classification for patients with acute PE, providing valuable insights for improved patient management.
- 30 August 2023
- Published by MDPI AG in Preprints.org
Open AccessAssociation of Blood Leukocytes and Hemoglobin with Hospital Mortality in Acute Pulmonary Embolism
This study aimed to assess the prognostic significance of total leukocyte count (TLC) and hemoglobin (Hb) levels upon admission for patients with acute pulmonary embolism (PE), considering the European Society of Cardiology (ESC) model for mortality risk. 1622 patients from a regional PE registry were included. Decision tree statistics were employed to evaluate TLC and Hb's prognostic value, both independently and in conjunction with the ESC model. Results indicated all-cause and PE-related in-hospital mortality rates of 10.7% and 6.5% respectively. Subgrouping patients based on TLC cutoff values (≤11.2, 11.2-16.84, >16.84 x10^9/L) revealed increasing all-cause mortality risks (7.0%, 11.8%, 30.2%). Incorporating Hb levels (≤126 g/L or above) further stratified the lowest risk group into two strata with all-cause mortality rates of 10.1% and 4.7%. Similar trends were observed for PE-related mortality. Notably, TLC improved risk assessment for intermediate-high risk patients within the ESC model, while Hb levels enhanced mortality risk stratification for lower risk PE patients in the ESC model for all-cause mortality. In conclusion, TLC and Hb levels upon admission can refine the ESC model's mortality risk classification for patients with acute PE, providing valuable insights for improved patient management.
- Open Access
- 23 May 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (11) , 1829
New-Onset Paroxysmal Atrial Fibrillation in the Setting of Acute Pulmonary Embolism Is Associated with All-Cause Hospital Mortality in Women but Not in Men
Background: Patients with acute pulmonary embolism (PE) may have various types of atrial fibrillation (AF). The role of AF in hemodynamic states and outcomes may differ between men and women. Methods: In total, 1600 patients (743 males and 857 females) with acute PE were enrolled in this study. The severity of PE was assessed using the European Society of Cardiology (ESC) mortality risk model. Patients were allocated into three groups according to their electrocardiography recordings taken during hospitalization: sinus rhythm, new-onset paroxysmal AF, and persistent/permanent AF. The association between the types of AF and all-cause hospital mortality was tested using regression models and net reclassification index (NRI) and integrated discrimination index (IDI) statistics with respect to sex. Results: There were no differences between the frequencies of the types of AF between men and women: 8.1% vs. 9.1% and 7.5% vs. 7.5% (p = 0.766) for paroxysmal and persistent/permanent AF, respectively. We found that the rates of paroxysmal AF significantly increased across the mortality risk strata in both sexes. Among the types of AF, the presence of paroxysmal AF had a predictive value for all-cause hospital mortality independent of mortality risk and age in women only (adjusted HR, 2.072; 95% CI, 1.274–3.371; p = 0.003). Adding paroxysmal AF to the ESC risk model did not improve the reclassification of patient risk for the prediction of all-cause mortality, but instead enhanced the discriminative power of the existing model in women only (NRI, not significant; IDI, 0.022 (95% CI, 0.004–0.063); p = 0.013). Conclusion: The occurrence of paroxysmal AF in female patients with acute PE has predictive value for all-cause hospital mortality independent of age and mortality risk.
- 23 May 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (11) , 1829
Open AccessNew-Onset Paroxysmal Atrial Fibrillation in the Setting of Acute Pulmonary Embolism Is Associated with All-Cause Hospital Mortality in Women but Not in Men
Background: Patients with acute pulmonary embolism (PE) may have various types of atrial fibrillation (AF). The role of AF in hemodynamic states and outcomes may differ between men and women. Methods: In total, 1600 patients (743 males and 857 females) with acute PE were enrolled in this study. The severity of PE was assessed using the European Society of Cardiology (ESC) mortality risk model. Patients were allocated into three groups according to their electrocardiography recordings taken during hospitalization: sinus rhythm, new-onset paroxysmal AF, and persistent/permanent AF. The association between the types of AF and all-cause hospital mortality was tested using regression models and net reclassification index (NRI) and integrated discrimination index (IDI) statistics with respect to sex. Results: There were no differences between the frequencies of the types of AF between men and women: 8.1% vs. 9.1% and 7.5% vs. 7.5% (p = 0.766) for paroxysmal and persistent/permanent AF, respectively. We found that the rates of paroxysmal AF significantly increased across the mortality risk strata in both sexes. Among the types of AF, the presence of paroxysmal AF had a predictive value for all-cause hospital mortality independent of mortality risk and age in women only (adjusted HR, 2.072; 95% CI, 1.274–3.371; p = 0.003). Adding paroxysmal AF to the ESC risk model did not improve the reclassification of patient risk for the prediction of all-cause mortality, but instead enhanced the discriminative power of the existing model in women only (NRI, not significant; IDI, 0.022 (95% CI, 0.004–0.063); p = 0.013). Conclusion: The occurrence of paroxysmal AF in female patients with acute PE has predictive value for all-cause hospital mortality independent of age and mortality risk.